top of page
Final_Vaccelerate.png

EVI is
leading immune

monitoring

activities in this

pan-European

vaccine trial network

as part of a €150 million

EU investment in research

to fight coronavirus variants

VACCELERATE

European Corona Vaccine Trial Accelerator

Vaccelerate-2021-04-20_7S_Turquoise_transp.png

Read more >>

Final_Vaccelerate.png

EVI is
leading immune

monitoring

activities in this

pan-European

vaccine trial network

as part of a €150 million

EU investment in research

to fight coronavirus variants

VACCELERATE

European Corona Vaccine Trial Accelerator

Read more >>

Final_Portfolio photo.png

We are

committed to

develop safe,

effective and

affordable vaccines

 

Check our latest updates

and new cross-cutting

activities

Explore >>

R&D PORTFOLIO

Discover EVI's vaccine

Male Scientist

Keen to further develop your skills in vaccine development?  

Open call

TRANSVAC2, coordinated by EVI, offers free training courses to provide fundamental and advanced knowledge on a wide-range of vaccine development-related topics.

Check out TRANSVAC2 trainings >>

logoTransvac_white.png

IMPROVING AND ACCELERATING VACCINE DEVELOPMENT IN EUROPE

Today's Catalyst for 

Tomorrow's Vaccines

dna-1811955_640.jpg
logoTransvac_white.png

IMPROVING AND ACCELERATING VACCINE DEVELOPMENT IN EUROPE

Are you a researcher developing a vaccine candidate? 

Open call

TRANSVAC2, coordinated by EVI, offers free high-quality technical services at all stages of the Vaccine R&D pipeline to support the development of prophylactic and therapeutic vaccines for human and veterinary use.

Check all Services available>>

dna-1811955_640.jpg
logoTransvac_white.png

IMPROVING AND ACCELERATING VACCINE DEVELOPMENT IN EUROPE

Are you a researcher developing a vaccine candidate? 

Open call

TRANSVAC2, coordinated by EVI, offers free high-quality technical services at all stages of the Vaccine R&D pipeline to support the development of prophylactic and therapeutic vaccines for human and veterinary use.

Check all Services available>>

Neglected Diseases

Today's Catalyst of Tomorrow's Vaccines

Emerging diseases 

Neglected and emerging infectious diseases disproportionately affect the lives of people and children living in low- and middle-income countries, causing sickness, disability and death to millions, and also represent a significant and growing threat worldwide.

Global
village
  Global 
  health 

This is a great place to tell your story and give people more insight into who you are, what you do, and why it’s all about you.

Neglected Diseases

mainly affect low income population

have the potential to cause global outbreaks

and epidemics

Today's Catalyst of Tomorrow's Vaccines

Emerging diseases 

Neglected and emerging infectious diseases disproportionately affect the lives of people and children living in low- and middle-income countries, causing sickness, disability and death to millions, and also represent a significant and growing threat worldwide.

Global
village

Vaccines are among the most successful and cost-effective public health tools for preventing diseases and death. Each year, more than three million lives are saved and millions more are protected from disease and disability, thanks to vaccination.

Vaccines, the way forward
OUR WORK

Diseases 

EVI has a Vaccine Projects' Portfolio that addresses critical R&D challenges and opportunities in five disease areas:

Malaria is caused by Plasmodium 

parasites and spread to people through mosquitoes. 90% of all cases occur in the WHO Africa Region.

Leishmaniasis is caused by a protozoan parasite and transmitted to humans by sandflies. Over 1 billion people are at risk from leishmaniasis.

IMG_5584_edited.jpg

Diarrhoeal diseases are the 2nd leading cause of death in children under five. Shigella and Enterotoxigenic E. coli are major causes of diarrhoea worldwide.

Nipah virus can be transmitted from animals (pigs, bats), contaminated food or directly between people. The case fatality rate ranges from 40% to 100%.

Zika is an emerging mosquito-borne virus. Zika virus infection during pregnancy can cause infants to be born with congenital Zika syndrome.

Image by National Cancer Institute

Cross-cutting Activities

EVI is committed to supporting vaccine development beyond individual vaccine candidates. EVI engages in initiatives aimed at creating harmonisation between stakeholders, promote networking and support access to vaccine infrastructures as well as capacity strengthening activities at the European and global level. 

EVI is committed to establishing a European vaccine R&D infrastructure to accelerate the development of prophylactic and therapeutic vaccines for human and animal health.

EVI is supporting the development and validation of non-animal approaches for testing quality of human and veterinary vaccines.

EVI seeks to create sustainable health networking, knowledge hubs and  facilitate 

cooperation of mutual benefit in health research and innovation.

EVI is working across Europe to harmonise key vaccine assays, through standardised lab procedures, preparations, and reagents, and by promoting their uptake and use.

OUR ACHIEVEMENTS

EVI at a glance

Since its inception in 1998, EVI has succeeded in establishing and maintaining an ‘enabling environment’ that accelerates vaccine development and has developed synergies and collaborations with multiple partners, including other Product Development Partnerships (PDPs), academia, research institutions, pharma and biotechnology companies, policy makers regulatory agencies and donors.

 

In 2020, EVI supports:

10 vaccine candidates

5 disease areas

6 vaccine candidates

in clinical development

​

bottom of page